CTL-4 Inhibitors in Lung Cancer Trials

I just want to start out with more of a global because we've heard lots of data or fair amount of data for the last few years about the issue of anti-CTLA4 plus PD-1 initially, EpiNivo. Now more recently, particularly a Dervitremi. I'm curious right now in general, outside of clinical trial, in what situations, if any, do you think about a combination like that? And also, in general, again, sort of a macro view of toxicity, Epi nivo, the way it's being given in lung cancer trials, and Dervit Remi.